UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Re-live UEG Week 2026 on Gutflix Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Audio / Video Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

FIBROSCAN (TRANSIENT ELASTOGRAPHY), CONTROLLED ATTENUATION PARAMETER, AND SHEAR WAVE SPEED MEASUREMENTS IN NORTH-CENTRAL NIGERIA

McHenry Stephen 1,2, Dashe Shepnaan M 2, Danhkole Adebayo Suday 2, Lukman Abdulrahaman Adelodun 3, Ruth Bello Adabe 3, Kintasha Anthony Perpetua 4, Mercy Isichei 5,2, Christian Isichei 5,6,2

Affiliations

1 Federal Medical Center Keffi/Jos University Teaching Hospital, Jos, Nigeria

2 Faith Alive Foundation, Jos, Nigeria

3 Federal Medical Center, Keffi, Nigeria

4 University of Abuja, Abuja, Nigeria

5 Jos University Teaching Hospital, Jos, Nigeria

6 Bhingham University Teaching Hospital, Jos, Nigeria

Summary

AI Generated

A study of 1,409 patients in north-central Nigeria found that higher BMI strongly predicts higher controlled attenuation parameter scores, indicating increased hepatic steatosis, with 19% showing varying degrees of steatosis and 48% having elevated BMI.

Among 1,409 participants (mean age 43.84 years, 64.84% male), the most common indication for Fibroscan was chronic hepatitis B (57.5%), followed by chronic hepatitis C, with alcohol consumption and suspected fatty liver disease accounting for 8.93% of indications
Approximately 81% had no steatosis (stage S0, less than 248 dB/m), while 19% had varying degrees of steatosis, with the largest steatosis group being S3 (280 dB/m and above) at 9.6%
BMI showed a strong positive correlation with CAP score (r=+0.461, p=0.001), and on multiple regression analysis, BMI was the only significant predictor of CAP score (B=4.09, p=0.0001)
About 48% of participants had higher-than-normal BMI, and approximately 20% had significant fibrosis (14.0 kPa and above) on transient elastography measurement
The findings demonstrate that obesity rates are increasing among adults in north-central Nigeria and that increasing BMI is associated with increasing degrees of hepatic steatosis in this population

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Non-invasive assessment of liver structure is an invaluable current practice of hepatology.
The rate of obesity is increasing globally. Africa is not an exception as obesity has become quite prevalent in many parts of Africa like Nigeria.
Steatosis (excessive fat in the liver) can be assayed in the liver using a controlled attenuation parameter (CAP) during transient elastography (TE).

Aims & Methods

All patients fasted for at least 3 hours prior to carrying out a Fibroscan. The level of fibrosis was recorded in kPa and the CAP in dB/m. The machine (Fibroscan Expert 630) also recorded the Shear wave speed (SWS) in meters per second. Height and weight were obtained using a Stadiometer and BMI was extrapolated. Biodata was obtained using a questionnaire

Results

One thousand four hundred and nine participants (1,409) were studied. The mean age was 43.84 (sd=14.27) years. About Sixty-five percent (64.84%) were males. The commonest (57.5%) indication for Fibroscan was Chronic Hepatitis B (CHBVI). Alcohol consumption and or suspicions of fatty liver disease made up about Nine percent (8.93%) of the indications. About 48% had higher-than-normal BMI.
About 81% had steatosis stage S0 (<248 dB/m). Nineteen percent had different degrees of steatosis. The largest group was S3 (280dB /m and above) with 9.6 %. Stage S1 (2458-267dB/m) was 5.7%. About 20% had significant fibrosis (14.0kPa and above) via TE measurement.
Age had a weak positive correlation (+0.185) with TE scores while BMI had a weak negative correlation (-0.162) with TE scores. On the other hand, the CAP score was strongly and positively (+0.461) correlated with BMI but negatively (-0.073) with SWS. P=0.001
On multiple regression, only BMI (B =4.09) significantly predicts CAP score by about 4 folds, p=0.0001.

Conclusion

The rate of obesity is increasing among adults in North-central Nigeria. Among this cohort, it’s clear that as BMI increases, the degree (Stage) of steatosis also increases.

Conference

UEG Week Copenhagen 2023

Topics

Hepatobiliary

Submission format

Abstract

Session

PP 07 Liver & biliary (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

COMORBIDITY BURDEN IN PATIENTS WITH ULCERATIVE COLITIS IN THE BIOLOGIC ERA: A REAL-WORLD ANALYSIS FROM THE USA

Paul Rowe

TRANS-ATLANTIC BURDEN OF ALCOHOL-ATTRIBUTABLE CIRRHOSIS AND ITS CONTRIBUTION TO HEART FAILURE IN UNITED STATES VS EUROPE (1990-2023): A SYSTEMATIC ANALYSIS OF YEARS LIVED WITH DISABILITY FROM THE GLOBAL BURDEN OF DISEASE 2023 STUDY

Aman Bakhsh

Can I trust elastography and blood-based non-invasive tests in case of ongoing drinking or active inflammation? Yes or no?

Ansgar Lohse

A is for alcohol-related liver disease

Elisa Pose

Health data informing clinical practice – what can nurses do to support the process

Shellie Radford

Radiological assessment of response for organ preservation: Can ctDNA help in early stage?

Sofia Gourtsoyianni

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

COMORBIDITY BURDEN IN PATIENTS WITH ULCERATIVE COLITIS IN THE BIOLOGIC ERA: A REAL-WORLD ANALYSIS FROM THE USA

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

COMORBIDITY BURDEN IN PATIENTS WITH ULCERATIVE COLITIS IN THE BIOLOGIC ERA: A REAL-WORLD ANALYSIS FROM THE USA

Monica Fahmy 1, Wassem Wasfy 1, Wedad Alnemari 2, Ahmed Harb 2, Boushra Raghib 1, Chibo Lee 3, Wendell Valdecantos 3, Paul Rowe 3

Affiliations

1 Sanofi, Dubai, United Arab Emirates

2 Sanofi, Riyadh, Saudi Arabia

3 Sanofi, Morristown, United States

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Despite advances in biologic therapies, a substantial proportion of patients with ulcerative colitis (UC) fail to achieve clinical remission, reflecting a persistent unmet need. Comorbidities in patients with UC influences treatment outcomes, yet their distribution across treatment lines remains insufficiently characterized in real-world settings.

Aims & Methods

The objective of this analysis was to assess and compare the burden of systemic and psychiatric comorbidities in patients with UC across different treatment paradigms, including biologic‑naïve, biologic‑treated, and immunomodulator (IM)-treated patients.
A descriptive, retrospective analysis was conducted using real-world US data from the Optum’s de-identified Market Clarity Data (Optum® Market Clarity) from Q4 2015 to Q1 2024. The patient journey mapper was used to identify patients with a confirmed diagnosis of UC and descriptively assess clinical characteristics, comorbidities, treatment patterns, and healthcare resource utilization (HCRU) (emergency room [ER] visits, hospitalizations and systemic corticosteroid use) in patients with UC naïve to or treated with biologics and/or immunomodulators (IM).

Results

A total of 720,630 patients with UC were included in this analysis. Of these, 7.1% (n=51,270) patients were prescribed biologics and 29.2% (n=210,150) were treated with IM. Among biologic-naïve, biologic-treated, and IM-treated patients, 39%, 39% and 43% were overweight or obese, respectively. Burden of systemic comorbidities remained high: chronic pulmonary diseases, chronic liver disease, and diabetes were the most commonly frequently observed systemic comorbidities in patients with UC. Nearly one-third (31%) of patients treated with biologics and half of the patients (49%) treated with IM had a mean Charlson Comorbidity Index (CCI) score of ≥3. Psychiatric and functional comorbid symptoms were highly prevalent across all cohorts: anxiety was documented in 50%, 51%, and 57% of biologic-naïve, biologic-treated, and IM-treated patients, respectively. Depression was reported in 42%, 38%, and 46%; fatigue in 59%, 57% and 65%; diarrhea in 53%, 69%, and 63%; and rheumatoid arthritis/osteoarthritis in 48%, 42%, and 15% of biologic-naïve, biologic-treated, and IM-treated patients, respectively. HCRU remained elevated in treated populations: ER visits occurred in 21% of biologic-naïve patients, 25% of biologic-treated and 32% of IM-treated patients; hospitalizations in 10%, 12% and 16%; and systemic corticosteroid use in 4%, 21% and 19%, respectively.

Conclusion

Despite treatment with biologic and IM therapies, patients with UC continue to experience a substantial comorbidity burden with both psychiatric and systemic comorbidities being highly prevalent. Importantly, these burdens persist across treatment paradigms and are accompanied by continued healthcare utilization, suggesting that treatment escalation alone does not fully mitigate the multidimensional impact of UC.

Disclosure

All authors are employees of Sanofi and may hold stock/stock options in the company

Event

UEG Week Barcelona 2026

Topics

IBD

Submission format

Abstract

Session

Lessons from large IBD real-world cohorts

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

COMORBIDITY BURDEN IN PATIENTS WITH ULCERATIVE COLITIS IN THE BIOLOGIC ERA: A REAL-WORLD ANALYSIS FROM THE USA

Paul Rowe

TRANS-ATLANTIC BURDEN OF ALCOHOL-ATTRIBUTABLE CIRRHOSIS AND ITS CONTRIBUTION TO HEART FAILURE IN UNITED STATES VS EUROPE (1990-2023): A SYSTEMATIC ANALYSIS OF YEARS LIVED WITH DISABILITY FROM THE GLOBAL BURDEN OF DISEASE 2023 STUDY

Aman Bakhsh

Can I trust elastography and blood-based non-invasive tests in case of ongoing drinking or active inflammation? Yes or no?

Ansgar Lohse

A is for alcohol-related liver disease

Elisa Pose

Health data informing clinical practice – what can nurses do to support the process

Shellie Radford

Radiological assessment of response for organ preservation: Can ctDNA help in early stage?

Sofia Gourtsoyianni

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

TRANS-ATLANTIC BURDEN OF ALCOHOL-ATTRIBUTABLE CIRRHOSIS AND ITS CONTRIBUTION TO HEART FAILURE IN UNITED STATES VS EUROPE (1990-2023): A SYSTEMATIC ANALYSIS OF YEARS LIVED WITH DISABILITY FROM THE GLOBAL BURDEN OF DISEASE 2023 STUDY

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

TRANS-ATLANTIC BURDEN OF ALCOHOL-ATTRIBUTABLE CIRRHOSIS AND ITS CONTRIBUTION TO HEART FAILURE IN UNITED STATES VS EUROPE (1990-2023): A SYSTEMATIC ANALYSIS OF YEARS LIVED WITH DISABILITY FROM THE GLOBAL BURDEN OF DISEASE 2023 STUDY

Elena Alupei 1, Ashesh Das 2, Krish Keswani 3, Laiba Manzoor 4, Mohamed El Shabrawi 5, Iman Khan 6, Digvijay Singh Rajawat 7, Riyakumari Patel 8, Dileep Kumar Veldi 9, Aman Bakhsh 10

Affiliations

1 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

2 Mayo Clinic, Rochester, United States

3 GMERS, Gotri, India

4 Dow University of Health Sciences, Karachi, Pakistan

5 Port Said University, Port Said, Egypt

6 Ziauddin Medical University, Karachi, Pakistan

7 AIIMS, Patna, India

8 Surat Municipal Medical College and Research Institute, Surat, India

9 Gayatri Vidhya Parishad, Visakhapatnam, India

10 Netaji Subhash Chandra Bose Medical College, Jabalpur, India

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Cirrhosis stemming from alcohol use, when complicated by heart failure, has emerged as a critical public health crisis with grave implications for both morbidity and mortality[1][2]. Despite progress in cardiology and hepatology, the convergence of these conditions presents a unique management paradox and a heavy disability burden[3]. Anticipating future trajectories and identifying regional disparities is vital for effective resource allocation and healthcare planning. This study evaluates the years lived with disability (YLD) attributed to this dual burden across the United States and Europe from 1990 to 2023, with projections extending to 2050.

Aims & Methods

We analyzed Global Burden of Disease data for cirrhosis due to alcohol use with heart failure complication across four geographic regions (USA, Central Europe, Eastern Europe, and Western Europe) from 1990 to 2023. Data were stratified by age group (15-49 years, 50-69 years, 70+ years) and sex. We calculated age-standardized YLD rates per 100,000 population with 95% uncertainty intervals (UI). Temporal trends were assessed using generalized additive models. Inequality metrics including Gini coefficients and Theil indices quantified inter-regional disparities. K-means clustering identified distinct disease trajectory patterns across 24 region-age-sex combinations. Time-series forecasting models projected burden through 2050 with 95% confidence intervals. Statistical analyses were performed using Python.

Results

Between 1990 and 2023 Western Europe maintained the highest burden throughout, with YLD rates increasing from 0.787 per 100,000 in 1990 to 1.012 per 100,000 in 2023, a 28.6% increase. Central Europe experienced the most dramatic relative increase of 82.9%, rising from 0.394 to 0.720 per 100,000. Eastern Europe demonstrated a 74.7% increase from 0.226 to 0.395 per 100,000, while the USA showed a 38.5% increase from 0.408 to 0.565 per 100,000. Pronounced age gradients were evident across all regions, with 70+ years populations experiencing 10 to 16 folds higher YLD rates compared to 15-49 years. In 2023, 70+ years YLD rates reached 1.855 per 100,000 in Western Europe, 1.140 per 100,000 in Central Europe, 1.090 per 100,000 in the USA, and 0.713 per 100,000 in Eastern Europe. Substantial sex disparities persisted, with male-to-female YLD ratios of 3.27 in Central Europe, 2.45 in Western Europe, 1.93 in the USA, and 1.86 in Eastern Europe. Inequality analysis revealed declining Gini coefficients from 0.286 in 1990 to 0.227 in 2023 for 15-49 years. Clustering analysis identified four distinct trajectory patterns, with Western Europe 70+ years males exhibiting unique non-monotonic trends peaking in 2005. Forecasts to 2050 project continued burden increases in the USA (+65.4%), Central Europe (+49.6%), and Eastern Europe (+66.6%), while Western Europe is projected to experience a 19.0% decline. Age-stratified projections indicate disproportionate increases with USA 70+ years rates projected to reach 1.893 per 100,000 by 2050, a 73.7% increase from 2023 levels.

Conclusion

This analysis underscores a mounting disability burden from alcohol-related cirrhosis and heart failure, characterized by deep age and sex inequities. The forecasted 50–75% increases in the USA, Central Europe, and Eastern Europe demand urgent alcohol-reduction strategies, particularly for aging populations. The 3.3-fold male predominance necessitates sex-specific interventions. While Western Europe’s decline may offer a potential roadmap for success, other regions must brace for increased demand in hepatology, cardiology, and palliative services.

References

1) Rasoul, D., Ajay, A., Abdullah, A., Mathew, J., Lee Wei En, B., Mashida, K., & Sankaranarayanan, R. (2023). Alcohol and Heart Failure. European cardiology, 18, e65. https://doi.org/10.15420/ecr.2023.12
2)Grobman, B., Mansur, A., & Lu, C. Y. (2024). Disparities in Heart Failure Deaths among Patients with Cirrhosis. Journal of clinical medicine, 13(20), 6153. https://doi.org/10.3390/jcm13206153
3) Tonon, M., & Piano, S. (2021). Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever. Clinical and molecular hepatology, 27(1), 94–96. https://doi.org/10.3350/cmh.2020.0305

Event

UEG Week Barcelona 2026

Topics

Mechanisms & Personalised Medicine Radiology & Imaging Hepatobiliary

Submission format

Abstract

Session

Liver cirrhosis: A cirrhotic conundrum - Diagnosis and evaluation

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

COMORBIDITY BURDEN IN PATIENTS WITH ULCERATIVE COLITIS IN THE BIOLOGIC ERA: A REAL-WORLD ANALYSIS FROM THE USA

Paul Rowe

TRANS-ATLANTIC BURDEN OF ALCOHOL-ATTRIBUTABLE CIRRHOSIS AND ITS CONTRIBUTION TO HEART FAILURE IN UNITED STATES VS EUROPE (1990-2023): A SYSTEMATIC ANALYSIS OF YEARS LIVED WITH DISABILITY FROM THE GLOBAL BURDEN OF DISEASE 2023 STUDY

Aman Bakhsh

Can I trust elastography and blood-based non-invasive tests in case of ongoing drinking or active inflammation? Yes or no?

Ansgar Lohse

A is for alcohol-related liver disease

Elisa Pose

Health data informing clinical practice – what can nurses do to support the process

Shellie Radford

Radiological assessment of response for organ preservation: Can ctDNA help in early stage?

Sofia Gourtsoyianni

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Can I trust elastography and blood-based non-invasive tests in case of ongoing drinking or active inflammation? Yes or no?

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Can I trust elastography and blood-based non-invasive tests in case of ongoing drinking or active inflammation? Yes or no?

Annalisa Cespiati 1, Ansgar Lohse 2

Affiliations

1 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

2 University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

Postgraduate Teaching Programme Barcelona 2026

Session

Avoid inflammation and intoxication: Management of autoimmune and alcohol-related liver disease

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

COMORBIDITY BURDEN IN PATIENTS WITH ULCERATIVE COLITIS IN THE BIOLOGIC ERA: A REAL-WORLD ANALYSIS FROM THE USA

Paul Rowe

TRANS-ATLANTIC BURDEN OF ALCOHOL-ATTRIBUTABLE CIRRHOSIS AND ITS CONTRIBUTION TO HEART FAILURE IN UNITED STATES VS EUROPE (1990-2023): A SYSTEMATIC ANALYSIS OF YEARS LIVED WITH DISABILITY FROM THE GLOBAL BURDEN OF DISEASE 2023 STUDY

Aman Bakhsh

Can I trust elastography and blood-based non-invasive tests in case of ongoing drinking or active inflammation? Yes or no?

Ansgar Lohse

A is for alcohol-related liver disease

Elisa Pose

Health data informing clinical practice – what can nurses do to support the process

Shellie Radford

Radiological assessment of response for organ preservation: Can ctDNA help in early stage?

Sofia Gourtsoyianni

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

A is for alcohol-related liver disease

Elisa Pose 1

Affiliations

1 Hospital Clínic of Barcelona - IDIBAPS, Barcelona, Spain

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Barcelona 2026

Topics

Primary Care

Session

Public health aspects related to GI and steatotic liver disease (SLD)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

COMORBIDITY BURDEN IN PATIENTS WITH ULCERATIVE COLITIS IN THE BIOLOGIC ERA: A REAL-WORLD ANALYSIS FROM THE USA

Paul Rowe

TRANS-ATLANTIC BURDEN OF ALCOHOL-ATTRIBUTABLE CIRRHOSIS AND ITS CONTRIBUTION TO HEART FAILURE IN UNITED STATES VS EUROPE (1990-2023): A SYSTEMATIC ANALYSIS OF YEARS LIVED WITH DISABILITY FROM THE GLOBAL BURDEN OF DISEASE 2023 STUDY

Aman Bakhsh

Can I trust elastography and blood-based non-invasive tests in case of ongoing drinking or active inflammation? Yes or no?

Ansgar Lohse

A is for alcohol-related liver disease

Elisa Pose

Health data informing clinical practice – what can nurses do to support the process

Shellie Radford

Radiological assessment of response for organ preservation: Can ctDNA help in early stage?

Sofia Gourtsoyianni

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Health data informing clinical practice – what can nurses do to support the process

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Health data informing clinical practice – what can nurses do to support the process

Shellie Radford 1

Affiliations

1 None, None, United Kingdom

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Barcelona 2026

Topics

Nurses

Session

Education of patients and staff

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

COMORBIDITY BURDEN IN PATIENTS WITH ULCERATIVE COLITIS IN THE BIOLOGIC ERA: A REAL-WORLD ANALYSIS FROM THE USA

Paul Rowe

TRANS-ATLANTIC BURDEN OF ALCOHOL-ATTRIBUTABLE CIRRHOSIS AND ITS CONTRIBUTION TO HEART FAILURE IN UNITED STATES VS EUROPE (1990-2023): A SYSTEMATIC ANALYSIS OF YEARS LIVED WITH DISABILITY FROM THE GLOBAL BURDEN OF DISEASE 2023 STUDY

Aman Bakhsh

Can I trust elastography and blood-based non-invasive tests in case of ongoing drinking or active inflammation? Yes or no?

Ansgar Lohse

A is for alcohol-related liver disease

Elisa Pose

Health data informing clinical practice – what can nurses do to support the process

Shellie Radford

Radiological assessment of response for organ preservation: Can ctDNA help in early stage?

Sofia Gourtsoyianni

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Radiological assessment of response for organ preservation: Can ctDNA help in early stage?

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Radiological assessment of response for organ preservation: Can ctDNA help in early stage?

Violaine Randrian 1, Sofia Gourtsoyianni 2

Affiliations

1 Centre Hospitalier Universitaire de Poitiers, Poitiers, France

2 School of Medicine, National & Kapodistrian University of Athens, Athens, Greece

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Barcelona 2026

Session

Organ preservation in colorectal cancer dos and don’ts

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

COMORBIDITY BURDEN IN PATIENTS WITH ULCERATIVE COLITIS IN THE BIOLOGIC ERA: A REAL-WORLD ANALYSIS FROM THE USA

Paul Rowe

TRANS-ATLANTIC BURDEN OF ALCOHOL-ATTRIBUTABLE CIRRHOSIS AND ITS CONTRIBUTION TO HEART FAILURE IN UNITED STATES VS EUROPE (1990-2023): A SYSTEMATIC ANALYSIS OF YEARS LIVED WITH DISABILITY FROM THE GLOBAL BURDEN OF DISEASE 2023 STUDY

Aman Bakhsh

Can I trust elastography and blood-based non-invasive tests in case of ongoing drinking or active inflammation? Yes or no?

Ansgar Lohse

A is for alcohol-related liver disease

Elisa Pose

Health data informing clinical practice – what can nurses do to support the process

Shellie Radford

Radiological assessment of response for organ preservation: Can ctDNA help in early stage?

Sofia Gourtsoyianni